Capricor Therapeutics Faces Securities Law Violation Lawsuit
DJS Law Group has notified investors of a class action lawsuit against Capricor Therapeutics, Inc. The suit alleges violations of federal securities laws, including §10(b) and Rule 10b-5.
DJS Law Group has alerted investors to a class action lawsuit filed against Capricor Therapeutics, Inc. The suit, targeting the NASDAQ-listed company (CAPR), alleges violations of federal securities laws, including Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
The lawsuit claims that Capricor made misleading statements to investors regarding the clinical trials of its investigational therapy, CAP-1002. Specifically, the allegations suggest the company failed to disclose or misrepresented information about the efficacy and safety of CAP-1002, thereby impacting the company's stock value.
DJS Law Group is encouraging investors who have incurred losses in Capricor stock to contact the firm to discuss their rights. The group is investigating whether the company's statements were factually misleading and if investors relied on this information.
Capricor Therapeutics is a biotechnology company focused on developing therapies for diseases with unmet medical needs. Its lead product candidate, CAP-1002, is being investigated for potential applications in treating certain cardiac conditions.